Winchester, MA, United States of America

Andrea R Schievella


Average Co-Inventor Count = 3.8

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 1998-2006

Loading Chart...
8 patents (USPTO):

Title: The Innovations of Andrea R Schievella

Introduction

Andrea R Schievella is a notable inventor based in Winchester, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of TNF receptor death domain ligand proteins. With a total of 8 patents to his name, Schievella's work has had a profound impact on the treatment of inflammatory conditions.

Latest Patents

Schievella's latest patents focus on novel TNF receptor death domain ('TNF-R1-DD') ligand proteins and their inhibitors. These patents disclose polynucleotides encoding the TNF-R1-DD ligand protein, along with vectors, host cells, and methods for producing the ligand protein. Additionally, pharmaceutical compositions containing the TNF-R1-DD ligand protein are described, as well as methods for treating inflammatory conditions and inhibiting TNF-R death domain binding. The patents also outline methods for identifying inhibitors of TNF-R death domain binding and the inhibitors identified through these methods.

Career Highlights

Andrea R Schievella has been associated with Genetics Institute, Inc., where he has contributed to groundbreaking research and development in his field. His innovative work has led to advancements in understanding and treating various inflammatory diseases.

Collaborations

Throughout his career, Schievella has collaborated with esteemed colleagues, including Lih-Ling Lin and Jennifer Chen. These collaborations have fostered a productive environment for innovation and research.

Conclusion

Andrea R Schievella's contributions to biotechnology and his innovative patents have significantly advanced the understanding of TNF receptor death domain ligand proteins. His work continues to influence the development of new therapeutic approaches for inflammatory conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…